Breast cancer detection developer Biofield of Atlanta has signed a three-year distribution agreement with Trilogy Critical Care of Johannesburg, South Africa. The agreement covers distribution of the Biofield Diagnostic System in South African and other southern African countries.
BDS measures electrical activity in the breast to detect epithelial cancers, including breast cancer. The company believes the device can be a useful adjunct to mammography in helping to reduce surgical biopsies on suspicious breast lesions.
By AuntMinnie.com staff writersDecember 7, 2001
Related Reading
Biofield to try again with FDA, September 18, 2001
Biofield begins Europe survey, August 31, 2000
Copyright © 2001AuntMinnie.com